Conclusion of non-exclusive drug rebate agreement pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Naproxen exclusive of syrup formulation (ATC code according to WHO: M01AE02)
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naproxen exklusive der Darreichung Sirup (ATC-Code nach WHO: M01AE02)
Germany · Erfurt
What the buyer is looking for
Siehe Kurzbeschreibung
Description as published (DE).
Contract
BuyerAOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen
TypeSupplies
Estimated valuevalue not published
Published30 June 2026
CategoryMedical equipment & pharma · CPV 33600000
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Hexal AG · Holzkirchen | 45 | 2013–2024 |
| Aliud Pharma GmbH · Laichingen | 41 | 2013–2021 |
| ratiopharm GmbH | 37 | 2016–2024 |
| betapharm Arzneimittel GmbH · Augsburg | 35 | 2013–2021 |
| axicorp Pharma B.V. · EC Den Haag | 30 | 2016–2021 |
From 13.7M documented awards · regular winners know this buyer's requirements — that is your competition.
How often this buyer tenders this
2019282
2020224
2021274
2022178
2023247
2024285
2025539
2026219
Who knows the rhythm prepares instead of reacting.
743
days until the deadline — Thursday 31 August at 21:59
How to bid
Read the full notice — Original + documents
Goes directly to this tender on Öffentliche Vergabe (Datenservice). The full specification and all annexes are there.
Tenders like this, every morning at 7:30 in your inbox.
Start free →